Skip to main content

Home/ Vitamin D/ Group items tagged receptor

Rss Feed Group items tagged

Matti Narkia

Vitamin D and calcium insufficiency-related chronic diseases: molecular and cellular pa... - 0 views

    Vitamin D and calcium insufficiency-related chronic diseases: molecular and cellular pathophysiology.
    Peterlik M, Cross HS.
    Eur J Clin Nutr. 2009 Dec;63(12):1377-86. Epub 2009 Sep 2.
    PMID: 19724293

    A compromised vitamin D status, characterized by low 25-hydroxyvitamin D (25-(OH)D) serum levels, and a nutritional calcium deficit are widely encountered in European and North American countries, independent of age or gender. Both conditions are linked to the pathogenesis of many degenerative, malignant, inflammatory and metabolic diseases. Studies on tissue-specific expression and activity of vitamin D metabolizing enzymes, 25-(OH)D-1alpha-hydroxylase and 25-(OH)D-24-hydroxylase, and of the extracellular calcium-sensing receptor (CaR) have led to the understanding of how, in non-renal tissues and cellular systems, locally produced 1,25-dihydroxyvitamin D3 (1,25-(OH)2D3) and extracellular Ca2+ act jointly as key regulators of cellular proliferation, differentiation and function. Impairment of cooperative signalling from the 1,25-(OH)2D3-activated vitamin D receptor (VDR) and from the CaR in vitamin D and calcium insufficiency causes cellular dysfunction in many organs and biological systems, and, therefore, increases the risk of diseases, particularly of osteoporosis, colorectal and breast cancer, inflammatory bowel disease, insulin-dependent diabetes mellitus type I, metabolic syndrome, diabetes mellitus type II, hypertension and cardiovascular disease. Understanding the underlying molecular and cellular processes provides a rationale for advocating adequate intake of vitamin D and calcium in all populations, thereby preventing many chronic diseases worldwide.
Matti Narkia

Olmesartan - Wikipedia, the free encyclopedia - 0 views

    "Olmesartan (trade names Benicar, Olmetec) is an angiotensin II receptor antagonist used to treat high blood pressure. The prodrug olmesartan medoxomil is marketed worldwide by Daiichi Sankyo, Ltd. and in the United States by Daiichi Sankyo, Inc. and in India by Ranbaxy Laboratories Ltd. under the trade name Olvance.

    Olmesartan may possess high affinity for the Vitamin D Receptor, based on molecular modeling studies[2], but these results have not been duplicated in clinical trials.

    Because of the role of the Vitamin D receptor in innate immunity[3], this would indicate that olmesartan has immune modulatory properties. This theory is currently the premise underlying the Marshall Protocol, which uses olmesartan to impose a chemical blockade on 1,25 Vitamin D as part of a treatment of sarcoidosis and other diseases. The Marshall Protocol asserts that, assuming the etiology of these diseases is based on infection by cell-wall-deficient bacteria, restoring proper Vitamin D ratios via olmesartan dosing, combined with pulsed antibiotic dosing, would result in a cure.!
Matti Narkia

The Relevance of Vitamin D Receptor (VDR) Gene Polymorphisms for Cancer: A Review of th... - 0 views

    The relevance of vitamin D receptor (VDR) gene polymorphisms for cancer: a review of the literature.
    Köstner K, Denzer N, Müller CS, Klein R, Tilgen W, Reichrath J.
    Anticancer Res. 2009 Sep;29(9):3511-36. Review.
    PMID: 19667145

    CONCLUSION: Significant associations with VDR polymorphisms have been reported in cancer of the breast (Fok1, Bsm1, Taq1, Apa1, poly (A)), prostate (Fok1, Bsm1, Taq1, poly (A)), skin (Fok1, Bsm1, A-1210), colorectum (Fok1, Bsm1), ovary (Fok1, Apa1) and bladder (Fok1), and in renal cell carcinoma (Taq1, Apa1). However, conflicting data have been reported for most malignancies. After careful evaluation of the actual literature, it can be summarized that data indicating an association of VDR polymorphisms and cancer risk are strongest for breast cancer (Bsm1, Fok1), prostate cancer (Fok1) and malignant melanoma (MM) (Fok1). Data indicating an association of VDR polymorphisms and cancer prognosis are strongest for prostate cancer (Fok1), breast cancer (Bsm1, Taq1), MM (Bsm1) and renal cell carcinoma (Taq1).
Matti Narkia

Vitamin D Receptor Expression in Normal, Premalignant, and Malignant Human Lung Tissue ... - 0 views

    Vitamin D receptor expression in normal, premalignant, and malignant human lung tissue.
    Menezes RJ, Cheney RT, Husain A, Tretiakova M, Loewen G, Johnson CS, Jayaprakash V, Moysich KB, Salgia R, Reid ME.
    Cancer Epidemiol Biomarkers Prev. 2008 May;17(5):1104-10.
    PMID: 18483332
    doi: 10.1158/1055-9965.EPI-07-2713

    onclusions: VDR expression spanned the lung carcinogenesis spectrum. Nuclear expression was similar across various histologies, whereas cytoplasmic expression decreased with increasing histologic grade. These results indicate that there is potential for the use of calcitriol as a chemopreventive agent against the development of lung cancer. (Cancer Epidemiol Biomarkers Prev 2008;17(5):1104-10)
Matti Narkia

Review and meta-analysis on vitamin D receptor polymorphisms and cancer risk -- Raimond... - 0 views

    Review and meta-analysis on vitamin D receptor polymorphisms and cancer risk.
    Raimondi S, Johansson H, Maisonneuve P, Gandini S.
    Carcinogenesis. 2009 Jul;30(7):1170-80. Epub 2009 Apr 29. Review.
    PMID: 19403841
Matti Narkia


    The vitamin D3 receptor (VDR) is an intracellular hormone receptor that specifically binds the active form of vitamin D (1,25-dihydroxyvitamin D3 or calcitriol) and interacts with target-cell nuclei to produce a variety of biologic effects
Matti Narkia

Calcitriol receptor - Wikipedia, the free encyclopedia - 0 views

    The calcitriol receptor, also known as the vitamin D receptor (VDR) and also known as NR1I1 (nuclear receptor subfamily 1, group I, member 1), is a member of the nuclear receptor family of transcription factors.[1] Upon activation by vitamin D, the VDR forms a heterodimer with the retinoid-X receptor and binds to hormone response elements on DNA resulting in expression or transrepression of specific geneproducts. In humans, the vitamin D receptor is encoded by the VDR gene.[2]
Matti Narkia

Vitamin D and the vitamin D receptor are critical for control of the innate immune resp... - 0 views


    The data point to a critical role for the VDR and 1,25(OH)2D3 in control of innate immunity and the response of the colon to chemical injury.

    Vitamin D and the vitamin D receptor are critical for control of the innate immune response to colonic injury.
    Froicu M, Cantorna MT.
    BMC Immunol. 2007 Mar 30;8:5.
    PMID: 17397543
Matti Narkia

Polymorphisms in the Vitamin D Receptor and Risk of Ovarian Cancer in Four Studies -- T... - 0 views

    Our results of an association with the Fok1 VDR polymorphism further support a role of the vitamin D pathway in ovarian carcinogenesis.

    Polymorphisms in the vitamin D receptor and risk of ovarian cancer in four studies.
    Tworoger SS, Gates MA, Lee IM, Buring JE, Titus-Ernstoff L, Cramer D, Hankinson SE.
    Cancer Res. 2009 Mar 1;69(5):1885-91. Epub 2009 Feb 17. Erratum in: Cancer Res. 2009 Jun 15;69(12):5267. Gate, Margaret A [corrected to Gates, Margaret A].
    PMID: 19223536
    doi: 10.1158/0008-5472.CAN-08-3515
Matti Narkia

Exapation of an ancient Alu short interspersed element provides a highly conserved vita... - 0 views


    We demonstrated that the VDRE in the CAMP gene originated from the exaptation of an AluSx SINE in the lineage leading to humans, apes, OWMs and NWMs and remained under purifying selection for the last 55-60 million years. We present convincing evidence of an evolutionarily fixed, Alu-mediated divergence in steroid hormone nuclear receptor gene regulation between humans/primates and other mammals. Evolutionary selection to place the primate CAMP gene under regulation of the vitamin D pathway potentiates the innate immune response and may counter the anti-inflammatory properties of vitamin D.

    Exaptation of an ancient Alu short interspersed element provides a highly conserved vitamin D-mediated innate immune response in humans and primates.
    Gombart AF, Saito T, Koeffler HP.
    BMC Genomics. 2009 Jul 16;10:321.
    PMID: 19607716
Matti Narkia

Vitamin D receptor gene polymorphism: association with Crohn's disease susceptibility -... - 0 views

    Vitamin D receptor gene polymorphism: association with Crohn's disease susceptibility.\nSimmons JD, Mullighan C, Welsh KI, Jewell DP.\nGut. 2000 Aug;47(2):211-4.\nPMID: 10896912 \ndoi:10.1136/gut.47.2.211
Matti Narkia

Vitamin D -- Dusso et al. 289 (1): F8 -- AJP - Renal Physiology - 0 views

    Dusso AS, Brown AJ, Slatopolsky E.
    Vitamin D.
    Am J Physiol Renal Physiol. 2005 Jul;289(1):F8-28. Review.
    PMID: 15951480 [PubMed - indexed for MEDLINE]
Matti Narkia

PLoS Medicine - A Prospective Study of Plasma Vitamin D Metabolites, Vitamin D Receptor... - 0 views

    Li H, Stampfer MJ, Hollis JBW, Mucci LA, Gaziano JM, et al. (2007)
    A Prospective Study of Plasma Vitamin D Metabolites, Vitamin D Receptor Polymorphisms, and Prostate Cancer.
    PLoS Med 4(3): e103
Matti Narkia

Vitamin D (Cholecalciferol, Calcitriol) - 0 views

    Bioactive vitamin D or calcitriol is a steroid hormone that has long been known for its important role in regulating body levels of calcium and phosphorus, and in mineralization of bone. More recently, it has become clear that receptors for vitamin D are present in a wide variety of cells, and that this hormone has biologic effects which extend far beyond control of mineral metabolism.

    The active form of vitamin D binds to intracellular receptors that then function as transcription factors to modulate gene expression. Like the receptors for other steroid hormones and thyroid hormones, the vitamin D receptor has hormone-binding and DNA-binding domains. The vitamin D receptor forms a complex with another intracellular receptor, the retinoid-X receptor, and that heterodimer is what binds to DNA. In most cases studied, the effect is to activate transcription, but situations are also known in which vitamin D suppresses transcription.

    Each of the forms of vitamin D is hydrophobic, and is transported in blood bound to carrier proteins. The major carrier is called, appropriately, vitamin D-binding protein. The halflife of 25-hydroxycholecalciferol is several weeks, while that of 1,25-dihydroxycholecalciferol is only a few hours.

    The vitamin D receptor binds several forms of cholecalciferol. Its affinity for 1,25-dihydroxycholecalciferol is roughly 1000 times that for 25-hydroxycholecalciferol, which explains their relative biological potencies
1 - 14 of 14
Showing 20 items per page